methyl)benzoic acid, and an ω-amino acid. Assembly of
(aminomethyl)benzoic acids substituted at the ortho, meta,
and para positions and ω-amino acids with different numbers
of the methylene unit would lead to a variety of cyclic RGD
models. As a part of the synthesis of a combinatorial library
of cyclic RGD models, we initially planned the syntheses
of 1a (R ) H) and 1b (R ) CH2Ph), containing m-
(aminomethyl)benzoic acids14d,15 and ω-aminovaleric acid.
Synthetic strategy for 1 is illustrated in Scheme 1. The cyclic
peptide 1 can be synthesized by palladium-catalyzed carbo-
nylative macrolactamization of 2. It would be of interest to
know the effect of the R-substituent in 2 in this cyclization.
The cyclization precursor 2 would be prepared by sequential
amidation of m-iodobenzylamines 3, Fmoc-Asp(Ot-Bu)-OH
(4), Fmoc-Gly-OH (5), Fmoc-Arg(Boc)2-OH (6), and N-Fmoc-
ω-aminovaleric acid (7).
Scheme 1. Strategy for the Synthesis of Cyclic RGD Model 1
The cyclization precursors 2 were prepared as shown in
Scheme 2. Coupling of amine 3a and Fmoc-Asp(Ot-Bu)-
OH (4) was performed using PyBrop-diisopropylethylamine
(DIEA) in CH2Cl2-DMF (9:1) at ambient temperature.16
Removal of the Fmoc group using diethylamine in acetoni-
Scheme 2. Synthesis of Cyclization Precursors 2
precursors as masked activated esters.11 It was also applied
to the construction of macrocyclic lactones.12,13 For example,
we reported a combinatorial synthesis of a 128-member
macrosphelide library, utilizing palladium-catalyzed carbo-
nylative macrolactonization on solid-phase.11d We report an
efficient synthesis of cyclic peptidic RGD models utilizing
palladium-catalyzed carbonylative macrolactamization.
Cyclic RGD models have been studied as a selective
integrin receptor antagonist.2,3,14 We designed RGD pepti-
domimetics 1 that contain a RGD sequence, an (amino-
(9) Balraju, V.; Reddy, S.; Periasamy, M.; Iqbal, J. Tetrahedron Lett.
2005, 46, 5207-5210.
(10) Balraju, V.; Dev, R. V.; Reddy, D. S.; Iqbal, J. Tetrahedron Lett.
2006, 47, 3569-3571.
(11) (a) Takahashi, T.; Inoue, H.; Tomida, S.; Doi, T.; Bray, A.
Tetrahedron Lett. 1999, 40, 7843-7846. (b) Takahashi, T.; Inoue, H.;
Yamamura, Y.; Doi, T. Angew. Chem., Int. Ed. 2001, 40, 3230-3233. (c)
Hashimoto, M.; Mori, A.; Inoue, H.; Nagamiya, H.; Doi, T.; Takahashi, T.
Tetrahedron Lett. 2003, 44, 1251-1254. (d) Takahashi, T.; Kusaka, S.;
Doi, T.; Sunazuka, T.; Omura, S. Angew. Chem., Int. Ed. 2003, 42, 5230-
5234. (e) Doi, T.; Inoue, H.; Tokita, M.; Watanabe, J.; Takahashi, T. J.
Comb. Chem. 2008, 10, 135-141.
(12) (a) Takahashi, T.; Nagashima, T.; Tsuji, J. Chem. Lett. 1980, 369-
372. (b) Takahashi, T.; Ikeda, H.; Tsuji, J. Tetrahedron Lett. 1980, 21,
3885-3888.
(13) Lu, S.-M.; Apler, H. Chem. Eur. J. 2007, 13, 5908-5916.
(14) (a) Aumailley, M.; Gurrath, M.; Mu¨ller, G.; Calvete, J.; Timpl, R.;
Kessler, H. FEBS Lett. 1991, 291, 50-54. (b) Lender, A.; Yao, W. Q.;
Sprengeler, P. A.; Spanevello, R. A.; Furst, G. T.; Hirschmann, R.; Smith,
A. B., III. Int. J. Peptide Protein Res. 1993, 42, 509-517. (c) Cheng, S.;
Craig, W. S.; Mullen, D.; Tschopp, J. F.; Dixon, D.; Pierschbacher, M. D.
J. Med. Chem. 1994, 37, 1-8. (d) Jackson, S.; DeGrado, W.; Dwivedi, A.;
Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.;
Wells, G.; Wexler, R.; Mousa, S.; Harlow, R. J. Am. Chem. Soc. 1994,
116, 3220-3230. (e) Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman,
S. L.; Jonczyk, A.; Kessler, H. J. Am. Chem. Soc. 1996, 118, 7461-7472.
(f) Dechantsreiter, M. A.; Planker, E.; Matha¨, B.; Lohof, E.; Ho¨lzemann,
G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. J. Med. Chem. 1999, 42,
3033-3049. (g) Oishi, S.; Kamano, T.; Niida, A.; Odagaki, Y.; Hamanaka,
N.; Yamamoto, M.; Ajito K.; Tamamura, H.; Otaka, A.; Fujii, N. J. Org.
Chem. 2002, 67, 6162-6173.
818
Org. Lett., Vol. 10, No. 5, 2008